Amarantus Bioscience Holdings Inc (AMBS)

[laurek]

Expert Comments:

"Amarantus BioScience Holdings Inc. has a transformative year ahead and a diverse pipeline of promising products. Its diagnostic test for Alzheimer's disease (AD), LymPro, should be launched in H214. It will be the first blood-based test available for AD in the U.S., where there are about 0.5m people diagnosed with AD each year. Profits from LymPro could be used to develop eltoprazine and mesencephalic astrocyte-derived neurotrophic factor (MANF). . .MANF could start clinical development in 2015 and has potential in many indications."
Jason Napodano, Zacks Small-Cap Research (4/25/14) "On April 21, 2014, Amarantus Bioscience Holdings Inc. announced financial results for the year ended Dec. 31, 2013. Having spent much of the past year cleaning up the balance sheet, the company now has the financial resources to drive its assets forward in the clinic." -Zacks Small-Cap Research

The Life Sciences Report Interview with David Lowe (3/26/14) "Amarantus BioScience Holdings Ltd.'s eltoprazine molecule is now in Phase 2b for Parkinson's disease levodopa-induced dyskinesia (PD-LID), as well as attention-deficit hyperactivity disorder (ADHD). Amarantus CEO Gerald Commissiong led the charge on the negotiation front and did a brilliant job. . .

The company has been focusing on some orphan indications, such as retinitis pigmentosa (RP); it is in preclinical development with mesencephalic astrocyte-derived neurotrophic factor (MANF) in not only RP, an orphan indication, but also in Parkinson's, with some grant funding from the Michael J. Fox Foundation for Parkinson's Research. . .we believe this molecule, MANF, is one of the jewels in the field. . .we have one or two other indications for MANF, as well as the Amarantus' lead compound, eltoprazine, which is in the clinic. . . More >

Jason Napodano, Seeking Alpha (2/18/14) "Amarantus BioScience Holdings Inc. has entered into a definitive agreement with certain existing shareholders to exercise outstanding warrants that will deliver, at a minimum, $3M in new capital to the company. . .over the next few months, we expect Amarantus to put this new cash to work in several places."

Jason Napodano, Seeking Alpha (11/19/13) "We believe fundamentals are improving at Amarantus BioScience Holdings Inc., both with respect to the development of MANF (Mesencephalic-astrocyte-derived Neurotrophic Factor) and LymPro, and on the balance sheet. These improvements are the primary reasons why we believe investors should buy the stock today. . .right now the fundamentals are pointing to a potential breakout in 2014.

http://www.thelifesciencesreport.com/pub/co/6082